MTF2

Across TCGA pan-cancer cohorts, MTF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTF2 data layer compared with 30 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MTF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and OV are the cancer types where MTF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.087	0.757	<.001	18	view →
UCEC	DFS	Median	All	0.965	0.623	.010	16	view →
OV	OS	Median	All	0.277	0.690	.013	6	view →
ESCA	OS	Median	II,III,IV	0.345	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTF2–SKCM (DFS)

Open the SKCM breakdown →